Jump Financial LLC Reduces Stock Position in Mirum Pharmaceuticals, Inc. $MIRM

Key Points

• Jump Financial LLC reduced its holdings in Mirum Pharmaceuticals by 58.0%, decreasing its share count to 15,823 after selling 21,811 shares in the first quarter.
• Various institutional investors, including CWM LLC and Tower Research Capital, have shown significant activity with Mirum Pharmaceuticals by either boosting their positions or purchasing new stakes.
• Mirum Pharmaceuticals reported a 64.1% year-over-year revenue increase of $127.79 million for the recent quarter while beating EPS estimates, indicating strong potential for growth.

Jump Financial LLC trimmed its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 58.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,823 shares of the company's stock after selling 21,811 shares during the period. Jump Financial LLC's holdings in Mirum Pharmaceuticals were worth $713,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC lifted its holdings in Mirum Pharmaceuticals by 2.1% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 16,685 shares of the company's stock worth $752,000 after purchasing an additional 339 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Mirum Pharmaceuticals by 3.8% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,998 shares of the company's stock valued at $495,000 after buying an additional 398 shares in the last quarter. CWM LLC grew its position in Mirum Pharmaceuticals by 259.4% in the first quarter. CWM LLC now owns 593 shares of the company's stock valued at $27,000 after acquiring an additional 428 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its stake in shares of Mirum Pharmaceuticals by 2.9% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 17,200 shares of the company's stock valued at $711,000 after purchasing an additional 487 shares in the last quarter. Finally, Allianz Asset Management GmbH grew its holdings in shares of Mirum Pharmaceuticals by 12.1% during the 1st quarter. Allianz Asset Management GmbH now owns 6,500 shares of the company's stock valued at $293,000 after purchasing an additional 700 shares during the last quarter.

Mirum Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ MIRM traded down $0.35 during mid-day trading on Thursday, hitting $74.27. 398,683 shares of the stock traded hands, compared to its average volume of 526,148. The company has a market cap of $3.73 billion, a price-to-earnings ratio of -61.27 and a beta of 0.92. The stock has a fifty day moving average price of $58.58 and a 200-day moving average price of $49.73. Mirum Pharmaceuticals, Inc. has a 52 week low of $36.86 and a 52 week high of $76.02. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.97 and a current ratio of 3.13.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.19. Mirum Pharmaceuticals had a negative net margin of 13.65% and a negative return on equity of 24.76%. The business had revenue of $127.79 million during the quarter, compared to the consensus estimate of $107.91 million. During the same quarter last year, the firm earned ($0.52) earnings per share. The business's revenue for the quarter was up 64.1% on a year-over-year basis. Research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on MIRM shares. Stifel Nicolaus set a $89.00 price target on shares of Mirum Pharmaceuticals and gave the stock a "buy" rating in a report on Monday, August 11th. HC Wainwright raised their price target on shares of Mirum Pharmaceuticals from $73.00 to $80.00 and gave the stock a "buy" rating in a research note on Thursday, August 7th. Raymond James Financial reaffirmed a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research note on Thursday, August 7th. JMP Securities set a $81.00 price objective on shares of Mirum Pharmaceuticals and gave the stock a "market outperform" rating in a report on Thursday, August 7th. Finally, Evercore ISI boosted their target price on Mirum Pharmaceuticals from $77.00 to $89.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $74.13.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 40,000 shares of the firm's stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $62.00, for a total transaction of $2,480,000.00. Following the sale, the chief executive officer owned 138,641 shares in the company, valued at approximately $8,595,742. This trade represents a 22.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jolanda Howe sold 10,000 shares of the firm's stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $58.00, for a total value of $580,000.00. Following the sale, the senior vice president directly owned 2,426 shares in the company, valued at approximately $140,708. This represents a 80.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 91,041 shares of company stock valued at $5,320,624 over the last 90 days. 14.36% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.